Posters presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference highlight the complex care ...
A comprehensive care approach can help people with ambulatory DMD maximize function and retain the ability to walk for as ...
Columnist Patrick Moeschen offers a retrospective of what he did and didn't know about living with muscular dystrophy over ...
Researchers combined advanced imaging techniques and theoretical physics to observe and explain how nanoclusters of the protein emerin form inside living cells. The study uncovers the molecular 'rules ...
Regenxbio has reported positive interim data from the Phase I/II portion of its Affinity Duchenne study, which is examining ...
UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...
Adeno-associated virus (AAV)–mediated gene therapy was one of the focal points of this year's Muscular Dystrophy Association conference. Here, Barry Byrne, MD, PhD, University of Florida, speaks to ...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and ...
2021;6(11):887-896. [2] AskBio Announces First Patient Dosed in Phase 1 / Phase 2 Trial of AB-1003 Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9). Available at: https ...
Solid Biosciences will present Phase 1/2 trial data for SGT-003 gene therapy targeting Duchenne muscular dystrophy at MDA Conference. Solid Biosciences Inc. will present data from its Phase 1/2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback